ASCO

Patients

ASCO 26: Three cancer survivors share lessons for the field

In honour of National Cancer Survivors' Day, we recount three patient testimonies and calls to action from ASCO Voices at ASCO 2026.

Oncology

ASCO 2026: Chinese firms take a front seat in oncology, with...

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

News

ASCO26: Celcuity punished as trial disappoints investors

Celcuity is still confident it has a winner with its breast cancer treatment, gedatolisib, but investors seem less convinced by new VIKTORIA-1 data.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

Oncology

ASCO 26: Precision medicine takes a village, with Carolyn So...

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

News

ASCO26: After negative adcomm, AZ builds case for oral SERD

AstraZeneca showcases new data from the SERENA-6 data of camizestrant in breast cancer that it hopes will get FDA's review of the drug back on track.

ASCO 26: Three cancer survivors share lessons for the field

ASCO 2026: Chinese firms take a front seat in oncology, with...

ASCO26: Celcuity punished as trial disappoints investors

ASCO26: In vivo CAR-Ts in the spotlight

ASCO 26: Precision medicine takes a village, with Carolyn So...

ASCO26: After negative adcomm, AZ builds case for oral SERD

Jen Norton appointed market access leader at EVERSANA

Discover a new era of healthcare panel engagement: Grounded ...

ASCO

Editor's Picks